Online Medical Journal, 08.07.2019
With molecular medicine
Molecular medicine offers patients with lung cancer the possibility of higher survival rates. As the "National Network of Genomic Medicine for Lung Cancer" reports, a new tailored therapy can be offered to every third affected person.
A therapy adapted to cancer mutation can increase medial survival rates.
© catalin / stock.adobe.com
BERLIN. Molecular diagnosis and the resulting treatment increase survival rates and the number of times that lung cancer has been diagnosed. This was emphasized Monday by representatives of the German Assistance against Cancer in Berlin.
The "National Lung Cancer Network for Genomic Medicine" can offer a third tailored therapy to each affected person, "said Network spokesperson Professor Jürgen Wolf, Medical Director of the Center for Integrated Oncology. This center has launched the treatment route, where patients must now be treated as completely as possible.
The network has been active for more than a year. Approximately 380 regional partners and 15 German oncology centers participate. involved
were also established oncologists and specialty cabinets, Wolf said.
AOKen and the Ersatzkassen had already announced their intention to enter into supply contracts with all centers on the model of the Cologne Treaty or had already done so.
The cost of the diagnostics was between 1500 and 2000 euros, said Wolf. During the first year after the entry of new oncological active ingredients into the market, the costs of therapy would generally exceed the threshold of 100,000 euros.
Objective: Extend to all types of tumors
In perspective, molecular diagnosis and therapy should be extended to all types of tumors. The beginning with lung cancer is due to the fact that here the survival rate compared to standard chemotherapy is the highest, Wolf said. This explains the commitment of funds at this stage.
Non-small cell lung cancer remains the leading cause of death in people diagnosed with cancer. On average, patients survive one year after diagnosis. This is true if they are conservatively treated with chemotherapy (see following graph),
Under the conditions of molecular medicine, that is to say, a therapy adapted to the respective mutation of the cancer, the median survival was increased to five years. Extrapolated, between 10,000 and 15,000 patient-years were lost because no tumor mutation test was performed, Wolf said.
Other contributions of this topic